Related Experiment Video
Updated: Jul 30, 2025
08:31
CRISPR/Cas9 Ribonucleoprotein-mediated Precise Gene Editing by Tube Electroporation
Published on: June 20, 2019
14.1K
CRISPR/Cas9 Genome Editing for Tissue-Specific In Vivo Targeting: Nanomaterials and Translational Perspective
Deepak Kumar Sahel1, Lalitkumar K Vora2, Aishwarya Saraswat3
1Department of Pharmacy, Birla Institute of Technology and Science-Pilani, BITS-Pilani, Vidya Vihar, Pilani, Rajasthan, 333031, India.
Summary
This review explores nonviral nanodelivery strategies for CRISPR/Cas9 gene editing. It covers advancements, challenges, and future directions for in vivo tissue-specific delivery of CRISPR/Cas9 components.
Area of Science:
- Biotechnology
- Molecular Biology
- Nanomedicine
Background:
- Clustered randomly interspaced short palindromic repeats (CRISPR) and Cas9 are bacterial immune systems repurposed for gene editing.
- CRISPR/Cas9 technology offers versatile applications including insertion/deletion, epigenome, and mRNA editing for various diseases.
Purpose of the Study:
- To review nonviral nanodelivery strategies for CRISPR/Cas9 gene editing.
- To discuss recent advancements, challenges, and future prospects of in vivo CRISPR/Cas9 delivery.
Main Methods:
- Focuses on nonviral nanodelivery systems for CRISPR/Cas9 components.
- Summarizes current research and preclinical surveillance of in vivo delivery strategies.
Main Results:
- Nanomaterials offer promising avenues for targeted in vivo delivery of CRISPR/Cas9.
- Significant progress has been made in developing strategies for tissue-specific delivery.
Conclusions:
- Nonviral nanodelivery is crucial for advancing in vivo CRISPR/Cas9 gene editing therapies.
- Overcoming delivery challenges is key to realizing the full therapeutic potential of CRISPR/Cas9.
Related Concept Videos
01:28CRISPR/Cas9 Genome Editing
80
The CRISPR-Cas system serves as a bacterial defense mechanism against invading genetic elements such as viruses and plasmids, forming the foundation for its adaptation as a powerful genome-editing tool. Originally discovered in prokaryotes, this system has been repurposed to revolutionize genetic engineering across a wide range of organisms, including plants, animals, and humans. The core component, Cas9, is an endonuclease derived from Streptococcus pyogenes, capable of introducing...
80
01:59CRISPR
52.5K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
52.5K
02:53CRISPR and crRNAs
17.1K
Bacteria and archaea are susceptible to viral infections just like eukaryotes; therefore, they have developed a unique adaptive immune system to protect themselves. Clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins (CRISPR-Cas) are present in more than 45% of known bacteria and 90% of known archaea.
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
17.1K
02:31Homologous Recombination
50.7K
The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...
50.7K